Targets › MTHFR
6 programs from 6 companies in 7 trials: 2 Phase 2, 2 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Psychiatry, Ophthalmology; next expected readout Dec 2026.
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. Represents a key regulatory connection between the folate and methionine cycles (Probable). (UniProt, P42898)
Open in Phaseline: the race on MTHFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Queen's University | L-methylfolate Reduced folate cofactor; active form of folate supporting one-carbon metabolism and neurot | MTHFR | Phase 4 | Generalized Anxiety Disorder | – |
| Assistance Publique - Hôpitaux de Paris | Modified FOLFIRINOX Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A, MTHFR, TYMS | Phase 3 | Rectal Cancer | Dec 2026 |
| Kyung Hee University Hospital at Gangdong | Leucovorin Reduced folate potentiator; enhances 5-FU activity | MTHFR | Phase 3 | Rectal Cancer | – |
| Southwest Autism Research & Resource Center | Levoleucovorin Calcium 5-methyltetrahydrofolate (active form of folate) - cofactor for one-carbon metabolism and | MTHFR | Phase 2 | Autism Spectrum Disorder | – |
| National Aeronautics and Space Administration (NASA) | Vitamin B-Complex Supplement One-carbon pathway optimizer; supplies methylated B vitamins (5-methyltetrahydrofolate, ri | MTHFR, SHM1, MTHFD1, ENOS | Phase 1 | Optic Disc Edema | Jul 2027 |
| Isofol Medical | Arfolitixorin 5,10-methenyltetrahydrofolate synthetase inhibitor; active metabolite of leucovorin for 5- | MTHFR | Phase 1 | Metastatic Colorectal Cancer (mCRC) | Nov 2028 |
Autism Spectrum Disorder (2) Rectal Cancer (2) Optic Disc Edema (1) Metastatic Colorectal Cancer (mCRC) (1) Generalized Anxiety Disorder (1)
small molecule (5)
Southwest Autism Research & Resource Center (1) Kyung Hee University Hospital at Gangdong (1) Assistance Publique - Hôpitaux de Paris (1) National Aeronautics and Space Administration (NASA) (1) Isofol Medical (1) Queen's University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.